Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients

Status Completed

Clinical Trial Summary

In cancer patients, the increase of troponin I soon after chemotherapy is a strong predictor of left ventricular dysfunction and poor cardiologic outcome. This information provides a rationale for the development of prophylactic strategies directed against chemotherapy-induced cardiotoxicity (CTIC). Activation of the renin-angiotensin system has been proved to be involved in the development and progression of cardiac dysfunction in several clinical settings, and has been suggested to have a role in the occurrence of CTIC. We investigated the role of treatment with ACE-inhibitors in the prevention of CTIC in high-risk cancer patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00292526
Study type	Interventional
Source	European Institute of Oncology
Contact
Status	Completed
Phase	Phase 4
Start date	November 2000
Completion date	November 2011

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05271162` - Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines	Phase 3
Recruiting	`NCT04262830` - Cancer Therapy Effects on the Heart
Completed	`NCT02909712` - Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania	Phase 2
Recruiting	`NCT04092309` - Effect of Angiotensin Converting Enzyme and Sacubitril Valsartan in Patients After Bone Marrow Transplantation	N/A
Recruiting	`NCT04790266` - Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Breast Cancer Patients
Enrolling by invitation	`NCT04305613` - Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
Not yet recruiting	`NCT05040867` - Exercise Prescription Guided by Heart Rate Variability in Breast Cancer Patients	N/A
Recruiting	`NCT05851053` - Breast Cancer Long-term Outcomes on Cardiac Functioning: a Longitudinal Study
Recruiting	`NCT05992337` - New Biomarkers in the Prediction of Chemotherapy-induced Cardiotoxicity.
Enrolling by invitation	`NCT04877899` - Mazankowski Alberta Heart Institute (MAHI) EchoGo Discovery 1 Protocol
Recruiting	`NCT05096338` - Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer
Recruiting	`NCT05078190` - Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer
Recruiting	`NCT04632407` - Can Flaxseed Prevent Broken Hearts in Women With Breast Cancer Study?	N/A
Completed	`NCT00543062` - Staccato Prochlorperazine Thorough QT/QTc	Phase 1
Recruiting	`NCT05159479` - Defining Robust Predictors of Chemotherapy Related Cardiotoxicity
Not yet recruiting	`NCT06005259` - Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity (SPIROTOX)	Phase 4
Recruiting	`NCT05406635` - Imaging Versus Cardiac Biomarker Monitored HER2 Directed Therapy in Patients With Breast Cancer	N/A
Recruiting	`NCT04047901` - Effect of Physical Training in Patients With Heart Failure Caused by Chemotherapy for Cancer Treatment	N/A
Terminated	`NCT03038997` - Early Detection of Cardiac Toxicity in Childhood Cancer Survivors
Completed	`NCT01246778` - Sunitinib and Atrial Trabeculae Contractility	N/A